New insights into designing hybrid nanoparticles for lung cancer: Diagnosis and treatment
Lung cancer is the foremost reason of death from cancers with broad genetic and epigenetic
diversity. Various strategies are clinically available for diagnosis and treatment of lung …
diversity. Various strategies are clinically available for diagnosis and treatment of lung …
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
Although recurrent gene fusions involving erythroblastosis virus E26 transformation-specific
(ETS) family transcription factors are common in prostate cancer, their products are …
(ETS) family transcription factors are common in prostate cancer, their products are …
Ensartinib (X-396) in ALK-positive non–small cell lung cancer: results from a first-in-human phase I/II, multicenter study
L Horn, JR Infante, KL Reckamp… - Clinical Cancer …, 2018 - AACR
Purpose: Evaluate safety and determine the recommended phase II dose (RP2D) of
ensartinib (X-396), a potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor …
ensartinib (X-396), a potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor …
Targeting anaplastic lymphoma kinase in lung cancer
AT Shaw, B Solomon - Clinical Cancer Research, 2011 - AACR
Several decades of cancer research have revealed a pivotal role for tyrosine kinases as key
regulators of signaling pathways, controlling cell growth and differentiation. Deregulation of …
regulators of signaling pathways, controlling cell growth and differentiation. Deregulation of …
A mouse model for EML4-ALK-positive lung cancer
M Soda, S Takada, K Takeuchi… - Proceedings of the …, 2008 - National Acad Sciences
EML4-ALK is a fusion-type protein tyrosine kinase that is generated in human non-small-cell
lung cancer (NSCLC) as a result of a recurrent chromosome inversion, inv (p21p23) …
lung cancer (NSCLC) as a result of a recurrent chromosome inversion, inv (p21p23) …
Anaplastic lymphoma kinase: signalling in development and disease
RH Palmer, E Vernersson, C Grabbe… - Biochemical …, 2009 - portlandpress.com
RTKs (receptor tyrosine kinases) play important roles in cellular proliferation and
differentiation. In addition, RTKs reveal oncogenic potential when their kinase activities are …
differentiation. In addition, RTKs reveal oncogenic potential when their kinase activities are …
A synthetic lethality–based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1
T Oike, H Ogiwara, Y Tominaga, K Ito, O Ando, K Tsuta… - Cancer research, 2013 - AACR
The occurrence of inactivating mutations in SWI/SNF chromatin-remodeling genes in
common cancers has attracted a great deal of interest. However, mechanistic strategies to …
common cancers has attracted a great deal of interest. However, mechanistic strategies to …
Clinical management of adverse events associated with lorlatinib
TM Bauer, E Felip, BJ Solomon, H Thurm… - The …, 2019 - academic.oup.com
Lorlatinib is a novel, highly potent, brain‐penetrant, third‐generation ALK/ROS1 tyrosine
kinase inhibitor (TKI), which has broad‐spectrum potency against most known resistance …
kinase inhibitor (TKI), which has broad‐spectrum potency against most known resistance …
A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
Purpose: Approximately 5% of lung adenocarcinomas harbor an EML4-ALK gene fusion
and define a unique tumor group that may be responsive to targeted therapy. However ALK …
and define a unique tumor group that may be responsive to targeted therapy. However ALK …
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
X Zhang, S Zhang, X Yang, J Yang, Q Zhou, L Yin… - Molecular cancer, 2010 - Springer
Background The anaplastic lymphoma kinase (ALK) gene is frequently involved in
translocations that lead to gene fusions in a variety of human malignancies, including …
translocations that lead to gene fusions in a variety of human malignancies, including …